Thyroid stimulating hormone levels and BRAFV600E mutation contribute to pathophysiology of papillary thyroid carcinoma: Relation to outcomes?

Sulaieva, Oksana; Черненко, О. В.; Chereshneva, Elizaveta V.; Цомартова, Д. А.; Ларін, О. С.

doi:10.1016/j.pathophys.2019.05.001

Cited by 10 publications

(10 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several studies revealed that PTC patients with coexisting HT exhibited less aggressive clinicopathologic characteristics, as manifested by lower rates of extrathyroidal extension and lymph node metastases (LNM) and showed a longer recurrence-free survival duration (Borowczyk et al, 2019;Graceffa et al, 2019;Konturek et al, 2014;Lun et al, 2013;Moon et al, 2018). Previous studies confirmed a higher rate of microcarcinoma as well as a decrease of LNM rate in patients with coexisting HT (Graceffa et al, 2019;Sulaieva. et al, 2019).…”

Section: Introductionmentioning

confidence: 99%

Hashimoto's thyroiditis attenuates progression of papillary thyroid carcinoma: deciphering immunological links

Sulaieva

Selezniov

Shapochka

et al. 2020

Heliyon

Self Cite

View full text Add to dashboard Cite

Although some studies have investigated the clinicopathologic relationships between papillary thyroid carcinoma (PTC) and Hashimoto's thyroiditis (HT), there is still no clear understanding of differences in tumor immune microenvironment for PTC with coexisting HT and HT effect on PTC progression. The aim of this study was to clarify immune-mediated mechanisms of coexisting HT, which might influence PTC progression. 30 patients with histologically confirmed conventional-type PTC and 30 patients with PTC and coexisting HT were enrolled in the study. To analyze the role of immune-mediated links between PTC and HT, immunohistochemical investigation was conducted to count the number of different immune cells including T-cytotoxic cells (CD8), plasma cells (CD138), Treg cells (FOXP3), mast cells (MCT), and M2 macrophages (CD163). It was shown that despite the high number of immune cells in the intact thyroid tissues of PTC patients with coexisting HT there were no significant differences in M2 macrophages, mast cells and Treg counts inside PTC with or without HT. PTC with HT was associated with a higher number of CD8þ cells (P < 0.001) reflecting the ability of immune system to generate and recruit T-cytotoxic cells in tumor area, which can explain the protective effect of HT on PTC progression. Lymph node metastases development was associated with an increased number of mast cells, M2 macrophages and Treg along with a decreased plasma cells count regardless of coexisting HT. However, we did not find significant differences in T-cytotoxic cells quantity in node-positive and node-negative patients with or without HT, which encourages further investigation of immune escape mechanisms in PTC.

show abstract

Section: Introductionmentioning

confidence: 99%

Hashimoto's thyroiditis attenuates progression of papillary thyroid carcinoma: deciphering immunological links

Sulaieva

Selezniov

Shapochka

et al. 2020

Heliyon

Self Cite

View full text Add to dashboard Cite

show abstract

“…The activated inflammatory response present in HT may result in oncogene mutations that eventually lead to the occurrence of PTC. 1,7,8,28 A visible increase in the incidence of PTC and HT co-existence has been noticed over the past 20 years. In this study, the rate of PTC with HT was 20.4%, which is consistent with the 20% to 85% range reported previously.…”

Section: Discussionmentioning

confidence: 99%

“…7 Papillary thyroid carcinoma (PTC) is the most common cancer of the endocrine system. 1,8,9 In 1955, Dailey et al 10 first suggested an association between HT and PTC, linking chronic inflammation to neoplastic changes. Since then, numerous epidemiological studies have confirmed a high level of coexistence between HT and PTC, ranging from 20% to 85%.…”

Section: Introductionmentioning

confidence: 99%

Influence Factors for Lymph Node Metastasis in Papillary Thyroid Carcinoma: Hashimoto’s Thyroiditis Has a Weak Effect on Central or Lateral Lymph Node Metastasis

Zhou

Chen²,

Sheng

et al. 2021

CMAR

View full text Add to dashboard Cite

Purpose:To analyze the effect of Hashimoto's thyroiditis (HT) concurrent with papillary thyroid cancer (PTC) on cervical lymph node metastasis (LNM). Methods: Two thousand nine hundred twenty-six patients who underwent thyroidectomy and lymph node dissection between January 2015 and December 2018 were enrolled in this study. Patient demographics and clinicopathologic features were analyzed. Results: Of the total enrolled patients, 598 (20.4%) had concurrent HT. There were 1482 PTC cases with N0, 1033 cases with N1a, and 411 cases with N1b. Patients with HT had lower frequency of extrathyroidal extension (ETE), lymphatic vascular (LV) invasion, high pathological T stage (III+IV) and central LNM rate. Stratifying central LNM by non-ETE or without intrathyroidal spreading, it was further found that central LNM rate in patients with HT was lower than that of patients without HT. However, there was no significant difference in the central LNM rate in patients with PTC stratified by ETE or intrathyroidal spreading. HT with PTC played a weak protective role in N1a, reducing the risk of N1a by 16.4%. Conversely, HT is a risk factor for N1b, increasing the risk by 1.336 times compared to patients without HT. TgAb is an independent risk factor for N1b, which appears related to the promotion of N1b by HT. Conclusion:In PTC, HT has a protective effect on central LNM and a risk effect on lateral LNM, although the difference was not significant. This weak protective effect on N1a is more obvious in PTC with less aggressive clinicopathologic characteristics. The risk effect of HT on N1b may be associated with TgAb.

show abstract

“…However, the comprehensive evaluation of the TSH levels impact in PTC development and prognosis is controversial. A number of studies recorded an increased risk of thyroid cancer associated with elevated TSH levels [9,11,12]. However, there is an opposite point of view which is supported by many other studies, or not any relations between TSH and PTC are reported [10,12,13].…”

Section: Introductionmentioning

confidence: 95%

Papillary thyroid cancer and thyroid stimulating hormone: does sex matter?

Черненко¹,

Сулаєва²

2019

Fiziol Zh

View full text Add to dashboard Cite

The relation between histopathological characteristics of papillary thyroid cancer (PTC) and thyroid functioning in patients of different sex was assessed. Levels of thyroid stimulating hormone (TSH) and thyroid hormones (fT3 and fT4) were measured in 576 patients (468 females and 108 males) with histologically confirmed PTC. Extrathyroid extension (ETE) of PTC, lymphovascular invasion (LVI) and lymph node metastasis (LNM) were assessed in patients of different sex. In addition, age, histological type and Hashimoto's thyroiditis (HT) were considered. We did not find sex differences in PTC staging. However, females demonstrated smaller tumor size and higher microcarcinoma rate, whereas PTC in men was related to a higher LNM incidence. Coexisting HT was found in 33.3% of the observed patients. HT rate was significantly higher in females than in males and was associated with elevated TSH, though, there was no statistically significant relationship between HT and thyroid hormone levels. Coexisting HT significantly decreased the risk of ETE (OR = 0.67; 95% CI 0.44-1.00; P = 0.05) and LNM (OR = 0.59; 95% CI 0.37-0.94; P = 0.028) among males with PTC. However, there was no significant impact of HT on ETE and LNM in females with PTC. The present study showed sex-related differences in TSH levels and microcarcinoma incidence associated with high rate of coexisting HT in females. Coexisting HT was associated with lower rate of LNM and ETE in males that could reflect a potentially protective role of HT in PTC progression.

show abstract

Thyroid stimulating hormone levels and BRAFV600E mutation contribute to pathophysiology of papillary thyroid carcinoma: Relation to outcomes?

Cited by 10 publications

References 34 publications

Hashimoto's thyroiditis attenuates progression of papillary thyroid carcinoma: deciphering immunological links

Hashimoto's thyroiditis attenuates progression of papillary thyroid carcinoma: deciphering immunological links

Influence Factors for Lymph Node Metastasis in Papillary Thyroid Carcinoma: Hashimoto’s Thyroiditis Has a Weak Effect on Central or Lateral Lymph Node Metastasis

Papillary thyroid cancer and thyroid stimulating hormone: does sex matter?

Contact Info

Product

Resources

About